Drugs / Bemnifosbuvir
Bemnifosbuvir
also known as
AT-527 · BEM · R07496998 · AT-511 · AT-511-hemisulfate salt · AT-527 free base · AT-527 is also know as R07496998 · Bemnifosbuvir hemisulfate · +2 more
Trials 28 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 120 trials | ||||||
| Phase 1 | NCT07272889 | Dec 2025 → Feb 2026 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06911320 | Apr 2025 → May 2026 overdue | impaired renal function disease | Atea Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06921941 | Apr → Jul 2025 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06356194 | Apr → May 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06204679 | Dec 2023 → Aug 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05905497 | Apr → May 2023 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05905484 | Apr → May 2023 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05724693 | Jan 2023 → Apr 2024 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05731843 | Jan → Mar 2023 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05618314 | Oct 2022 → Jun 2024 | impaired renal function disease | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05256732 | Feb → Aug 2022 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05154123 | Nov → Dec 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05137626 | Nov → Dec 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05004415 | Jul → Aug 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04877769 | Apr → Aug 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04865445 | Apr → May 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04849299 | Apr → May 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04784000 | Mar → Apr 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04711187 | Nov 2020 → Sep 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03219957 | Jul 2017 → Jun 2018 | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04309734 | Oct 2021 → Jun 2022 | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05904470 | May 2023 → Dec 2024 | chronic hepatitis C virus infection, cirrhosis of liver | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04709835 | Feb → Sep 2021 | COVID-19 | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT04019717 | Jun 2019 → Jan 2020 | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07037277 | Jun 2025 → Dec 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868264 | Apr 2025 → Sep 2026 expected | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05629962 | Nov 2022 → Apr 2024 | COVID-19 | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04889040 | Apr → Dec 2021 | COVID-19 | Hoffmann-La Roche | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04396106 Comparator | May 2020 → Jan 2022 | COVID-19 | Atea Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemnifosbuvir | “A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of a Single Oral Dose of Bemnifosbuvir/Ruzasvir Fixed Dose Combination on the Pharmacokinetics of Digoxin and...” NCT06921941 ↗12“A Phase 1, Open-Label Study to Evaluate the Potential Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir and Food-Drug Interaction in Healthy Adult Subjects” NCT05731843 ↗ |
| Known as | AT-511 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095404 ↗ |
| Known as | AT-511-hemisulfate salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095404 ↗ |
| Known as | AT-527 | “Bemnifosbuvir (AT-527)” NCT05724693 ↗ |
| Known as | AT-527 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095404 ↗ |
| Known as | AT-527 is also know as R07496998 | “AT-527 is also know as R07496998” NCT05154123 ↗ |
| Known as | BEM | “A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)” NCT06356194 ↗7“A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)” NCT06204679 ↗ “Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination” NCT06911320 ↗ “Drug: single dose Bemnifosbuvir (BEM)” NCT05724693 ↗ “Bemnifosbuvir (BEM; AT-527) Tablets” NCT05904470 ↗ “Bemnifosbuvir (BEM)” NCT05905497 ↗ “Bemnifosbuvir (BEM)” NCT05629962 ↗ “Bemnifosbuvir (BEM)” NCT05905484 ↗ |
| Known as | Bemnifosbuvir hemisulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095404 ↗ |
| Known as | BEMNIFOSBUVIR SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095404 ↗ |
| Known as | R07496998 | “Other Names: AT-527 is also known as R07496998” NCT04849299 ↗3“Other Names: AT-527 is also know as R07496998” NCT04865445 ↗ “AT-527 Formulation 1 (R07496998)” NCT04711187 ↗ “AT-527 (R07496998)” NCT05004415 ↗ |
| Known as | RO7496998 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04889040 ↗ |
| Action | Inhibit | “inhibitor of the hepatitis C virus (HCV) NS5B polymerase” PMID 31570394 ↗ Sep 2019 |
| Modality | Other / unclassified | “AT-527 is a novel modified guanosine nucleotide prodrug inhibitor” PMID 31570394 ↗ Sep 2019 |
| Route | Oral | “Ascending doses of AT-527 administered orally.” NCT03219957 ↗ |